Reported by Segye Ilbo / Jun 11, 2024.
HoneyNaps, a South Korean AI sleep data analysis company, announced on June 11 that it held consultations with approximately 160 global institutions, including hospitals and research institutes in the U.S., during the 'Sleep 2024' conference held in Houston from June 1 to 5.
Being the only South Korean company participating in the American sleep conference for three consecutive years since 2022, HoneyNaps presented its paper on the second-generation digital therapy for insomnia (DTx), titled "A Digital Therapy Based on Real-time Sleep Sensing Data," along with its AI sleep disorder diagnosis solution, SOMNUM, which received FDA approval in August last year.
At the exhibition, HoneyNaps showcased solutions under the main theme "All-in-one for Sleep Medicine," focusing on "Diagnosis & Analysis" and "Monitoring & Therapeutics."
The AI diagnosis software, SOMNUM, has been upgraded to optimize sleep data interpretation from polysomnography (PSG) and home sleep apnea testing (HSAT). Users can click on key indicators to view explainable AI (XAI) diagnostic and analytical information in a pop-up window.
Additionally, the highly anticipated SOMNUM Scanning system integrated with SOMNUM PAX, a central sleep monitoring solution and SOMNUM Medella, a digital insomnia treatment was introduced to enhance efficiency for sleep medicine professionals and researchers. This system addresses the low compliance rates often associated with existing wearable devices and eliminates the inconvenience of having to process data manually.
A representative from HoneyNaps stated, "Thanks to our FDA approval, we received over 160 requests for demonstrations and consultations from medical professionals." They added, "Discussions are ongoing for strategic partnerships with major global pharmaceutical and medical device companies, and based on these achievements, we plan to expand our overseas sales through a local subsidiary in Boston by the end of the year."
Comments